0
Special Features
Clinical and economic outcomes of medication therapy management services: The Minnesota experience
Brian J. Isetts, PhD, BCPS, FAPhA; Stephen W. Schondelmeyer, PharmD, MA (Pub Adm), PhD; Margaret B. Artz, PhD; Lois A. Lenarz, MD; Alan H. Heaton, PharmD; Wallace B. Wadd, PharmD; Lawrence M. Brown, PharmD, PhD; Robert J. Cipolle, PharmD
J Am Pharm Assoc (2003) 2008;48:203-214. doi:10.1331/JAPhA.2008.07108

Abstract

Objectives  To (1) provide medication therapy management (MTM) services to patients, (2) measure the clinical effects associated with the provision of MTM services, (3) measure the percent of patients achieving Healthcare Effectiveness Data and Information Set (HEDIS) goals for hypertension and hyperlipidemia in the MTM services intervention group in relationship to a comparison group who did not receive MTM services, and (4) compare patients’ total health expenditures for the year before and after receiving MTM services.

Design  Prospective study.

Setting  Six ambulatory clinics in Minnesota from August 1, 2001, to July 31, 2002.

Patients  285 intervention group patients with at least 1 of 12 medical conditions using prestudy health claims; 126 comparison group patients with hypertension and 126 patients with hyperlipidemia were selected among 9 clinics without MTM services for HEDIS analysis.

Intervention  MTM services provided by pharmacists to BlueCross BlueShield health plan beneficiaries in collaboration with primary care providers.

Main Outcome Measures  Drug therapy problems resolved; percentage of patients’ goals of therapy achieved and meeting HEDIS measures for hypertension and hypercholesterolemia. Total health expenditures per person were measured for a 1-year period before and after enrolling patients in MTM services.

Results  637 drug therapy problems were resolved among 285 intervention patients, and the percentage of patients’ goals of therapy achieved increased from 76% to 90%. HEDIS measures improved in the intervention group compared with the comparison group for hypertension (71% versus 59%) and cholesterol management (52% versus 30%). Total health expenditures decreased from $11,965 to $8,197 per person (n = 186, P < 0.0001). The reduction in total annual health expenditures exceeded the cost of providing MTM services by more than 12 to 1.

Conclusion  Patients receiving face-to-face MTM services provided by pharmacists in collaboration with prescribers experienced improved clinical outcomes and lower total health expenditures. Clinical outcomes of MTM services have chronic care improvement and value-based purchasing implications, and economic outcomes support inclusion of MTM services in health plan design.

Sign In
APhA Members 
Welcome to JAPhA.org! Please log in below using your APhA username and password. Update your APhA profile.
Not a Subscriber
New to JAPhA? Become an APhA member to receive a full subscription to both the print and online editions.

OR

Register for a FREE limited account to benefit from personalization features such as alerts.

References

Mikeal RL, Brown TP, Lazarus HL, Vinson MC.  Quality of pharmaceutical care in hospitals Am J Hosp Pharm.  1975;32:567–74.[PubMed]
 
Smith WE, Benderev K. Levels of pharmaceutical care: A theoretical model Am J Hosp Pharm.  1991;48:540–6.[PubMed]
 
Isetts BJ, Brown LM, Schondelmeyer SW, Lenarz LA.  Quality assessment of a collaborative approach for decreasing drug-related morbidity and achieving therapeutic goals Arch Intern Med.  2003;163:1813–20.[PubMed][CrossRef]
 
 Medicare Payment Advisory Commission. Report to the Congress: Medicare coverage of nonphysician practitioners.  Washington, D.C.:  Medicare Payment Advisory Commission;  2002:21–6.
 
 Public law no. 108-173: Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Accessed at www.ustreas.gov/offices/public-affairs/hsa/pdf/pl108-173.pdf, January 28, 2008.
 
Beebe M, Dalton JA, Duffy C, et al. Current Procedural Terminology: CPT 2006. Chicago:  American Medical Association;  2006.
 
Isetts BJ, Buffington DE.  CPT code-change proposal: National data on pharmacists' medication therapy management services J Am Pharm Assoc.  2007;47:491–5.
 
Beebe M, Dalton JA, Duffy C, et al. Current Procedural Terminology: CPT 2008.  Chicago:  American Medical Association;  2008.
 
 American Medical Association. CPT changes 2006: an insider's view. Chicago:  American Medical Association;  2005:309–12.
 
Bluml BJ.  Definition of medication therapy management: Development of professionwide consensus J Am Pharm Assoc.  2005;45:566–72.
 
Bluml BM, McKenney JM, Cziraky MJ.  Pharmaceutical care services and results in Project ImPACT: Hyperlipidemia J Am Pharm Assoc.  2000; 40:157–73.
 
Cranor CW, Christensen DB.  The Asheville Project: Short-term outcomes of a community pharmacy diabetes care program J Am Pharm Assoc.  2003;43:149–59.
 
Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: The Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP).  Arch Intern Med.  2002;162:1149–55.[PubMed]
 
Erickson SR, Slaughter MS, Halapy H. Pharmacists' ability to influence outcomes of hypertension therapy Pharmacotherapy.  1997;17:140–7.[PubMed]
 
Shibley MC, Pugh CB.  Implementation of pharmaceutical care services for patients with dyslipidemias by independent community pharmacy practitioners Ann Pharmacother.  1997;31:713–9.[PubMed]
 
Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: Effects on health services utilisation, costs, and patient outcomes. Accessed at www.cochrane.org/reviews/en/ab000336.html, April 7,  2004.
 
Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit.  JAMA.  1999;282:267–70.[PubMed]
 
Kucukarslan SN, Peters M, Mlynarek M, Nafziger DA.  Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units Arch Intern Med.  2003;163:2014–8.[PubMed]
 
Chiquette E, Amoato MG, Bussey HI.  Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs Arch Intern Med.  1998;158:1641–7.[PubMed]
 
Kaushal R, Bates DW. The clinical pharmacist's role in preventing adverse drug events. In: Shojania K, Duncan B, McDonald K, Wachter RM, eds.  Making health care safer: a critical analysis of patient safety practices.  Rockville, Md.:  Agency for Healthcare Research and Quality;  2001[Evidence Report/Technology Assessment no. 43; AHRQ publication 01-E058].
 
Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM.  Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: Results of the pharmacist in heart failure assessment recommendation and monitoring (PHARM) study Arch Intern Med.  1999;159:1939–45.[PubMed]
 
Cranor CW, Christensen DB.  The Asheville Project: Long-term clinical and economic outcomes of a community pharmacy diabetes care program J Am Pharm Assoc.  2003;43:173–84.
 
Schumock GT, Butler MG, Meek PD, et al. Evidence of the economic benefit of clinical pharmacy services: 1996-2000.  Pharmacotherapy.  2003;23:113–32.[PubMed]
 
Johnson JA, Bootman JL.  Drug-related morbidity and mortality and the economic impact of pharmaceutical care Am J Health Syst Pharm.  1997;54:554–8.[PubMed]
 
Schumock GT, Meek PD, Ploetz, PA, Vermeulen LC.  Economic evaluation of clinical pharmacy service: 1988-1995 Pharmacotherapy.  1996;16:1188–208.[PubMed]
 
Hatoum HT, Akhras K. 1993 bibliography: A 32-year literature review on the value and acceptance of ambulatory care provided by pharmacists Ann Pharmacother.  1993;27:1106–19.[PubMed]
 
Hatoum HT, Catizone C, Hutchinson RA, Purohit A. Eleven year review of the pharmacy literature: Documentation of the value and acceptance of clinical pharmacy Drug Intell Clin Pharm.  1986;20:33–48.[PubMed]
 
Hammond RW, Schwartz AH, Campbell MJ, et. al. Collaborative drug therapy management by pharmacists: 2003.  Pharmacotherapy.  2003;23:1210–25.[PubMed]
 
Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness Milbank Q.  1996;74:511–44.[PubMed]
 
Von Korff M, Gruman J, Schaefer J, et al. Collaborative management of chronic illness.  Ann Intern Med.  1997;19:1097–102.
 
Wagner EH.  Chronic disease management: What will it take to improve care for chronic illness Eff Clin Pract.  1998;1:1–4.
 
Bodenheimer TS, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness JAMA.  2002;288:1775–9.[PubMed]
 
Wagner EH, Glasgow RE, Davis C, et al. Quality improvement in chronic illness care: A collaborative approach.  Jt Comm J Qual Improv.  2001;27:63–80.[PubMed]
 
 RAND Corporation. Improving chronic illness care evaluation. Accessed at www.rand.org/health/ICICE, December 7,  2007.
 
Porter ME, Teisberg EO.  Redefining health care: creating value-based competition on results.  Boston:  Harvard Business School Press;  2006.
 
Meyer J, Rybowski L, Eichler R. Theory and reality of value-based purchasing: Lessons from the pioneers. Accessed at www.ahrq.gov/qual/meyerrpt.htm, July 14,  2007.
 
Pham HH, Schrag D, O'Malley AS, et al. Care patterns in Medicare and their implications for pay for performance.  N Engl J Med.  2007;356:1130–9.[PubMed]
 
Glickman SW, Ou F, DeLong ER, et al. Pay for performance, quality of care, and outcomes in acute myocardial infarction.  JAMA.  2007;297:2373–80.[PubMed]
 
Webber A. Building the business case for quality improvement J Am Pharm Assoc.  2005;45:437–42.
 
Isetts BJ, Schondelmeyer SW, Heaton AH, et al. Effects of collaborative drug therapy management on patients' perceptions of care and health-related quality of life.  Res Social Adm Pharm.  2006;2:129–42.[PubMed]
 
Cipolle RJ, Strand LM, Morley PC.  Pharmaceutical care practice: the clinician's guide.  New York:  McGraw-Hill;  2004.
 
Isetts BJ, Sorensen TD.  Use of a student-driven, university-based pharmaceutical care clinic to define the highest standards of patient care Am J Pharm Educ.  1999;63:443–9.
 
Cipolle RJ, Strand LM, Morley PC.  Pharmaceutical care practice.  New York:  McGraw-Hill;  1998.
 
Brown LM.  A peer-review study of the quality of care provided by pharmaceutical care practitioners in an ambulatory care clinic setting.  Minneapolis:  University of Minnesota;  2003[doctoral dissertation].
 
Darling H, Isham GJ.  HEDIS 2001 technical specifications. Vol. 2.  Washington, D.C.:  National Committee for Quality Assurance;  2000.
 
 National Committee for Quality Assurance. HEDIS 2001 national averages for commercial insurance products: NCQA quality compass 2001 Accessed with permission at www.ncqa.org/communications/news/somc2001.htm by Michele Taylor, Analyst, Information Products, National Committee for Quality Assurance,November 30,  2006.
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Please read the other comments before you post yours. Comments are moderated and will appear on the site at the discertion of the editorial staff.
* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content

Customize your page view by dragging & repositioning the boxes below.

JAPhA Articles
Topic Collections
PubMed Articles
Drug safety evaluation of olanzapine pamoate. Expert Opin Drug Saf 2013;12(6):897-903.
Advertisement
 
  • Print
  • PDF Download
  • Email
  • Share
  • Get Citation
  • Submit Comment
  • Article Alerts
    Please Wait... Processing your request... Please Wait.
    You must sign in to sign-up for alerts.

    Please confirm that your email address is correct, so you can successfully receive this alert.

  • Letters To Editor
  • Reprints